search
Back to results

Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS

Primary Purpose

Postural Orthostatic Tachycardia Syndrome (POTS), POTS, Orthostatic Intolerance

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Pyridostigmine
Digoxin
Placebo
Sponsored by
New York Medical College
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Postural Orthostatic Tachycardia Syndrome (POTS) focused on measuring Postural Orthostatic Tachycardia Syndrome (POTS), POTS, Orthostatic Intolerance, Digoxin, Pyridostigmine, Mestinon

Eligibility Criteria

15 Years - 30 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria for POTS patients:

POTS patients referred for day to day orthostatic intolerance with greater than 3 symptoms for greater than 3 months and will have the diagnosis of symptomatic postural tachycardia made during a screening tilt table test :

  • dizziness
  • nausea and vomiting
  • palpitations
  • fatigue
  • headache
  • exercise intolerance
  • blurred vision
  • abnormal sweating heat.

Healthy control subjects:

  • normal physical examination, and normal electrocardiographic and echocardiographic evaluations.
  • Only those free from heart disease, and from systemic illness will be eligible to participate.
  • This excludes patients with illnesses and disease states known to be associated with endothelial cell dysfunction such as diabetes, renal disease, congestive heart failure, systemic hypertension, acute and chronic inflammatory diseases, neoplasm, immune mediated disease, trauma, morbid obesity and peripheral vascular disease.

At the time of testing all patients and control subjects must refrain from vasoactive drugs for two weeks.

Exclusion Criteria for both POTS and healthy controls:

  • An active medical condition that may explain the diagnosis
  • A previous medical condition with undocumented resolution that may explain the diagnosis
  • any systemic or overt structural, arrhythmic or myopathic cardiovascular disease
  • any illnesses known to produce autonomic dysfunction such as diabetes, heart disease, renal disease, systemic hypertension, acute and chronic inflammatory diseases, neoplastic disease, immune mediated disease, major trauma and burns, morbid obesity and peripheral vascular disease will also be excluded.
  • Cigarette smokers will be excluded.
  • Past or present major psychiatric disorder
  • Substance abuse within 2 years before onset of symptoms.

Sites / Locations

  • New York Medical College/Bradhurst building

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Pyridostigmine and Placebo

Digoxin and Placebo

Arm Description

Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day

Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day

Outcomes

Primary Outcome Measures

Cardiovagal Baroreflex during orthostatic stress
Cardiovagal Baroreflex during orthostatic stress in unmedicated POTS patients compared to unmedicated control subjects during each angle of incremental tilt. The unmedicated baroreflex measurement will be repeated in POTS patients to similar measurements after treatment with placebo, pyridostigmine or digoxin. Baroreflex measurements will be obtained using the standard "modified Oxford" technique.
Cognitive ability during orthostatic stress
. Cognitive ability during orthostatic stress in unmedicated POTS patients compared to unmedicated control subjects during each angle of incremental tilt. Cognitive ability will be repeated in POTS patients to similar measurements after treatment with placebo, pyridostigmine or digoxin. Cognitive ability will be assessed with a standard 2-Back test in which patients identify identical alphabetic characters appearing 2 characters before the current displayed character in a sequence of 29 characters.

Secondary Outcome Measures

Cardiac output measure by inert gas breathing technique
Cardiac output measure by inert gas breathing technique. Cardiac output is the amount of blood pumped by the heart in one minute. The technique uses the Innocor system in which the relative levels of two inert gases - one blood soluble and one insoluble component - are measured over a few respirations (about 5 breaths or 15 seconds). The rate of disappearance of the soluble gas from the alveolar space is proportional to the flow of blood perfusing the lungs and equals the cardiac output.
Arterial blood pressure, and mean arterial pressure defined by the time average blood pressure over the cardiac cycle
Arterial blood pressure in mmHg over each cardiac cycle will be collected using finger photoplethysmography. The arterial pressure is reported as an aggregate of 3 extracted quantities: the systolic blood pressure which is the maximum blood pressure over a cardiac cycle; the diastolic blood pressure which is the minimum blood pressure over a cardiac cycle; and the mean blood pressure which is the average blood pressure over a cardiac cycle.
Heart rate
systemic vascular resistance defined by the ratio of mean arterial pressure to cardiac output

Full Information

First Posted
August 14, 2017
Last Updated
September 27, 2022
Sponsor
New York Medical College
Collaborators
National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT03261570
Brief Title
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS
Official Title
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in Postural Tachycardia Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
July 1, 2017 (Actual)
Primary Completion Date
June 1, 2022 (Actual)
Study Completion Date
June 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
New York Medical College
Collaborators
National Institutes of Health (NIH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Postural tachycardia syndrome (POTS), is the chronic form of orthostatic intolerance associated with excessive upright tachycardia, and occurs predominantly in young females (>85%). Among its most troubling symptoms are lightheadedness, fatigue, and decreased memory often called "brain fog" by patients. Task-related neurovascular coupling (NVC) links neural activity to an increase in CBF known as "functional hyperemia". Although memory task performance and NVC deteriorated with angle of tilt in POTS but not healthy controls, cerebral blood flow (CBF) remained similar to control. Instead, the investigators observed extensive narrow band low frequency (0.07-0.13 Hz) oscillations in BP (OBP) that entrained and amplified oscillations in CBF (OCBF). OBP and OCBF increased with tilt angle and caused impaired working memory and reduced functional hyperemia. The cardiovagal baroreflex couples BP to HR to buffer BP changes. The investigators hypothesize that the cardiovagal baroreflex becomes progressively impaired with orthostasis in POTS, but not in healthy volunteers, and accounts for OBP, OCBF, and loss of NVC; further, improving the baroreflex reduces OBP, OCBF and Brain Fog in POTS.
Detailed Description
Orthostatic intolerance is defined by debilitating upright symptoms that are relieved by sitting or lying. Symptoms include upright lightheadedness, fatigue, confusion, and decreased memory called 'Brain Fog' by patients. The most common chronic form is Postural Tachycardia Syndrome (POTS), characterized by excessive upright tachycardia without hypotension. Of note, >85% of POTS patients are female. The proposal that Brain Fog was caused by reduced cerebral blood flow (CBF) has been disproven, because graded incremental upright tilt failed to demonstrate difference in mean CBF compared to healthy volunteers. Nevertheless, memory task performance deteriorates with angle of tilt as does task-related neurovascular coupling (NVC), which links neural activity to an increase in CBF known as "functional hyperemia". The investigators have previously observed that large low frequency (0.07-0.13 Hz) oscillations in BP (OBP), which entrained and amplified oscillations in CBF (OCBF), increased with tilt angle and were associated with impaired working memory and reduced functional hyperemia. The sympathetic baroreflex remains intact and HR is excessively increased in the absence of parasympathetic counterregulation. The cardiovagal baroreflex couples BP to HR to buffer BP changes. Large low frequency BP oscillations, representing a resonance within the sympathetic baroreflex loop, occur if there is central hypovolemia, an intact sympathetic baroreflex, and reduced parasympathetic buffering of BP by HR; conditions found in upright POTS. This leads to the following hypothetical paradigm: ↓Cardiovagal Baroreflex → ↑OBP → ↑↑OCBF → ↓NVC → ↓working memory. Therefore, in this application, the investigators hypothesize that the cardiovagal baroreflex is impaired in POTS while supine, becomes further impaired with orthostasis, and accounts for OBP, OCBF, and loss of NVC. Further, the investigators propose that improving the cardiovagal baroreflex improves hemodynamics and Brain Fog in POTS patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postural Orthostatic Tachycardia Syndrome (POTS), POTS, Orthostatic Intolerance
Keywords
Postural Orthostatic Tachycardia Syndrome (POTS), POTS, Orthostatic Intolerance, Digoxin, Pyridostigmine, Mestinon

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Early Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
51 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pyridostigmine and Placebo
Arm Type
Active Comparator
Arm Description
Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
Arm Title
Digoxin and Placebo
Arm Type
Active Comparator
Arm Description
Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
Intervention Type
Drug
Intervention Name(s)
Pyridostigmine
Other Intervention Name(s)
Mestinon
Intervention Description
60mg by mouth
Intervention Type
Drug
Intervention Name(s)
Digoxin
Intervention Description
0.5 (500mcg) by mouth
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Lactulose 50mg by mouth
Primary Outcome Measure Information:
Title
Cardiovagal Baroreflex during orthostatic stress
Description
Cardiovagal Baroreflex during orthostatic stress in unmedicated POTS patients compared to unmedicated control subjects during each angle of incremental tilt. The unmedicated baroreflex measurement will be repeated in POTS patients to similar measurements after treatment with placebo, pyridostigmine or digoxin. Baroreflex measurements will be obtained using the standard "modified Oxford" technique.
Time Frame
1 year
Title
Cognitive ability during orthostatic stress
Description
. Cognitive ability during orthostatic stress in unmedicated POTS patients compared to unmedicated control subjects during each angle of incremental tilt. Cognitive ability will be repeated in POTS patients to similar measurements after treatment with placebo, pyridostigmine or digoxin. Cognitive ability will be assessed with a standard 2-Back test in which patients identify identical alphabetic characters appearing 2 characters before the current displayed character in a sequence of 29 characters.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Cardiac output measure by inert gas breathing technique
Description
Cardiac output measure by inert gas breathing technique. Cardiac output is the amount of blood pumped by the heart in one minute. The technique uses the Innocor system in which the relative levels of two inert gases - one blood soluble and one insoluble component - are measured over a few respirations (about 5 breaths or 15 seconds). The rate of disappearance of the soluble gas from the alveolar space is proportional to the flow of blood perfusing the lungs and equals the cardiac output.
Time Frame
1 year
Title
Arterial blood pressure, and mean arterial pressure defined by the time average blood pressure over the cardiac cycle
Description
Arterial blood pressure in mmHg over each cardiac cycle will be collected using finger photoplethysmography. The arterial pressure is reported as an aggregate of 3 extracted quantities: the systolic blood pressure which is the maximum blood pressure over a cardiac cycle; the diastolic blood pressure which is the minimum blood pressure over a cardiac cycle; and the mean blood pressure which is the average blood pressure over a cardiac cycle.
Time Frame
1 year
Title
Heart rate
Time Frame
1 year
Title
systemic vascular resistance defined by the ratio of mean arterial pressure to cardiac output
Time Frame
1 year

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria for POTS patients: POTS patients referred for day to day orthostatic intolerance with greater than 3 symptoms for greater than 3 months and will have the diagnosis of symptomatic postural tachycardia made during a screening tilt table test : dizziness nausea and vomiting palpitations fatigue headache exercise intolerance blurred vision abnormal sweating heat. Healthy control subjects: normal physical examination, and normal electrocardiographic and echocardiographic evaluations. Only those free from heart disease, and from systemic illness will be eligible to participate. This excludes patients with illnesses and disease states known to be associated with endothelial cell dysfunction such as diabetes, renal disease, congestive heart failure, systemic hypertension, acute and chronic inflammatory diseases, neoplasm, immune mediated disease, trauma, morbid obesity and peripheral vascular disease. At the time of testing all patients and control subjects must refrain from vasoactive drugs for two weeks. Exclusion Criteria for both POTS and healthy controls: An active medical condition that may explain the diagnosis A previous medical condition with undocumented resolution that may explain the diagnosis any systemic or overt structural, arrhythmic or myopathic cardiovascular disease any illnesses known to produce autonomic dysfunction such as diabetes, heart disease, renal disease, systemic hypertension, acute and chronic inflammatory diseases, neoplastic disease, immune mediated disease, major trauma and burns, morbid obesity and peripheral vascular disease will also be excluded. Cigarette smokers will be excluded. Past or present major psychiatric disorder Substance abuse within 2 years before onset of symptoms.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julian M. Stewart, M.D., Ph.D.
Organizational Affiliation
New York Medical College
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Medical College/Bradhurst building
City
Hawthorne
State/Province
New York
ZIP/Postal Code
10532
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS

We'll reach out to this number within 24 hrs